Explores the potential of psychedelics as medicine and the intersections of politics, science, and psychedelics • Explores the tumultuous history of psychedelic research, the efforts to restore psychedelic therapies, and the links between psychiatric drugs and mental illness • Offers non-technical summaries of the most recent, double-blind, placebo-controlled studies with MDMA, psilocybin, LSD, and ayahuasca • Includes the work of Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker Embracing the revival of psychedelic research and the discovery of new therapeutic uses, clinical psychologist Dr. Richard Louis Miller discusses what is happening today in psychedelic medicine--and what will happen in the future--with top researchers and thinkers in this field, including Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker. Dr. Miller and his contributors cover the tumultuous history of early psychedelic research brought to a halt 50 years ago by the U.S. government as well as offering non-technical summaries of the most recent studies with MDMA, psilocybin, LSD, and ayahuasca. They explore the biochemistry of consciousness and the use of psychedelics for self-discovery and healing. They discuss the use of psilocybin for releasing fear in the terminally ill and the potential for MDMA-assisted psychotherapy in the treatment of PTSD. They examine Dr. Charles Grob’s research on the indigenous use and therapeutic properties of ayahuasca and Dr. Gabor Mate’s attempt to transport this plant medicine to a clinical setting with the help of Canada’s Department of National Health. Dr. Miller and his contributors explore the ongoing efforts to restore psychedelic therapies to the health field, the growing threat of overmedication by the pharmaceutical industry, and the links between psychiatric drugs and mental illness. They also discuss the newly shifting political climate and the push for new research, offering hope for an end to the War on Drugs and a potential renaissance of research into psychedelic medicines around the world.

This handbook reviews promising applications of psychedelics in treatment of such challenging psychiatric problems as posttraumatic stress disorder, major depression, substance use disorders, and end-of-life anxiety. Experts from multiple disciplines synthesize current knowledge on psilocybin, MDMA, ketamine, and other medical hallucinogens. The volume comprehensively examines these substances' neurobiological mechanisms, clinical effects, therapeutic potential, risks, and anthropological and historical contexts. Coverage ranges from basic science to practical clinical considerations, including patient screening and selection, dosages and routes of administration, how psychedelic-assisted sessions are structured and conducted, and management of adverse reactions.

Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psychological, physiological, and social problems. More than a decade ago, the U.S. government lifted its ban on all testing of psychedelic substances. Winkelman and Sessa now provide updated scientific research and applications of these substances, now moving into approved categories of medicine. The text is an up-to-date assessment of the latest advances in the field of psychedelic medicine, covering the use of LSD, psilocybin, MDMA, ayahuasca, and other substances to augment psychotherapies for a range of disorders. It discusses medical and psychiatric concerns, clinical efficacy and safety, ethical considerations, and neuroscience findings regarding the psychedelic compounds. Topics covered include an overview of psychiatric applications of psychedelics; treatments for addictions and depressive disorders; effects of psychedelics on inflammation and neuroplasticity; evidence for clinical applications of DMT, ayahuasca, and cannabidiol; psychedelic treatment of sociopathic disorders; microdosing psychedelics; training psychedelic therapists; and community-based harm reduction approaches to managing psychedelic crises.

This volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action. Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds.

First published in 1979, Psychedelic Drugs Reconsidered is regarded by many as the most comprehensive, accurate, and accessible analysis of psychedelic drugs for the general reader. It records the extensive history of scientific research on, and societal experience with, psychedelic drugs. The Lindesmith Center reprint edition features a new introduction by the authors on recent developments in psychedelic research, as well as a preface by Dr. Ethan Nadelmann, director of the Lindesmith center.

This is a book about the intersections of three dimensions. The first is the way social scientists and historians treat the history of psychiatry and healing, especially as it intersects with psychedelics. The second encompasses a reflection on the substances themselves and their effects on bodies. The third addresses traditional healing, as it circles back to our understanding of drugs and psychiatry. The chapters explore how these dimensions are distinct, but deeply intertwined, themes that offer important insights into contemporary healing practices. The intended audience of the volume is large and diverse: neuroscientists, biologists, medical doctors, psychiatrists, psychologists; mental health professionals interested in the therapeutic application of psychedelic substances, or who work with substance abuse, depression, anxiety, and PTSD; patients and practitioners of complementary and alternative medicine; ethnobotanists and ethnopharmacologists; lawyers, criminologists, and other specialists in international law working on matters related to drug policy and human rights, as well as scholars of religious studies, anthropologists, sociologists, and historians; social scientists concerned both with the history of science, medicine, and technology, and concepts of health, illness, and healing. It has a potentially large international audience, especially considering the increasing interest in “psychedelic science” and the growing spread of the use of traditional psychoactives in the West.

LSD's short but colorful history in North America carries with it the distinct cachet of counterculture and government experimentation. The truth about this mind-altering chemical cocktail is far more complex—and less controversial—than generally believed. Psychedelic Psychiatry is the tale of medical researchers working to understand LSD’s therapeutic properties just as escalating anxieties about drug abuse in modern society laid the groundwork for the end of experimentation at the edge of psychopharmacology. Historian Erika Dyck deftly recasts our understanding of LSD to show it as an experimental substance, a medical treatment, and a tool for exploring psychotic perspectives—as well as a recreational drug. She recounts the inside story of the early days of LSD research in small-town, prairie Canada, when Humphry Osmond and Abram Hoffer claimed incredible advances in treating alcoholism, understanding schizophrenia and other psychoses, and achieving empathy with their patients. In relating the drug’s short, strange trip, Dyck explains how concerns about countercultural trends led to the criminalization of LSD and other so-called psychedelic drugs—concordantly opening the way for an explosion in legal prescription pharmaceuticals—and points to the recent re-emergence of sanctioned psychotropic research among psychiatric practitioners. This challenge to the prevailing wisdom behind drug regulation and addiction therapy provides a historical corrective to our perception of LSD’s medical efficacy.

Summarizes Grof's experiences and observations from more than forty years of research into non-ordinary states of consciousness. This accessible and comprehensive overview of the work of Stanislav Grof, one of the founders of transpersonal psychology, was specifically written to acquaint newcomers with his work. Serving as a summation of his career and previous works, this entirely new book is the source to introduce Grof's enormous contributions to the fields of psychiatry and psychology, especially his central concept of holotropic experience, where holotropic signifies "moving toward wholeness." Grof maintains that the current basic assumptions and concepts of psychology and psychiatry require a radical revision based on the intensive and systematic research of holotropic experience. He suggests that a radical inner transformation of humanity and a rise to a higher level of consciousness might be humankind's only real hope for the future. "It's rare to find a textbook that is both extremely informative and enjoyable to read. Psychology of the Future has to be one of the first ones I've ever come across ... Each chapter brought an entirely new concept, theory, or method that was just as engaging as the previous one." — Dr. Tami Brady, TCM Reviews "This book is by a pioneering genius in consciousness research. It presents the full spectrum of Grof's ideas, from his earliest mappings of using LSD psychotherapy, to his clinical work with people facing death, to his more recent work with holotropic breathing, to his latest thoughts about the cosmological implications of consciousness research and the prospects for dealing with an emerging planetary crisis. Grof has always been one of the most original thinkers in the transpersonal field, and his creativity has kept pace with the maturity of his overall vision." -- Michael Washburn, author of Transpersonal Psychology in Psychoanalytic Perspective "Grof offers an outstanding contribution to the ever-growing debate about the nature of human consciousness and about the place of humankind in the cosmos. If more psychiatrists could be persuaded that human consciousness transcends the limitations of the physical brain, and instead is but an aspect of what may best be described as 'cosmic consciousness,' we could not only expect treatment modalities to change, but we could also anticipate the possibility of culture-wide rethinking of the basic presuppositions of modern cosmology, the cosmology that grounds Western institutions, ideologies, and beliefs about the nature of personhood." -- Michael E. Zimmerman, author of Contesting Earth's Future: Radical Ecology and Postmodernity Stanislav Grof, MD, is a psychiatrist with more than fifty years of experience in research of non-ordinary states of consciousness. He has been Principal Investigator in a psychedelic research program at the Psychiatric Research Institute in Prague, Czechoslovakia; Chief of Psychiatric Research at the Maryland Psychiatric Research Center; Assistant Professor of Psychiatry at the Johns Hopkins University; and Scholar-in-Residence at the Esalen Institute. He is currently Professor of Psychology at the California Institute of Integral Studies, conducts professional training programs in holotropic breathwork, and gives lectures and seminars worldwide. He is one of the founders and chief theoreticians of transpersonal psychology and the founding president of the International Transpersonal Association (ITA). In 2007, he was granted the prestigious Vision 97 award from the Vaclav and Dagmar Havel Foundation in Prague. He is the author and editor of many books, including The Adventure of Self-Discovery: Dimensions of Consciousness and New Perspectives in Psychotherapy and Inner Exploration; Ancient Wisdom and Modern Science; Beyond the Brain: Birth, Death, and Transcendence in Psychotherapy; The Cosmic Game: Explorations of the Frontiers of Human Consciousness; and Human Survival and Consciousness Evolution; all published by SUNY Press.

The rise—and fall—of research into the therapeutic potential of LSD. After LSD arrived in the United States in 1949, the drug's therapeutic promise quickly captured the interests of psychiatrists. In the decade that followed, modern psychopharmacology was born and research into the drug's perceptual and psychological effects boomed. By the early 1960s, psychiatrists focused on a particularly promising treatment known as psychedelic therapy: a single, carefully guided, high-dose LSD session coupled with brief but intensive psychotherapy. Researchers reported an astounding 50 percent success rate in treating chronic alcoholism, as well as substantial improvement in patients suffering from a range of other disorders. Yet despite this success, LSD officially remained an experimental drug only. Research into its effects, psychological and otherwise, dwindled before coming to a close in the 1970s. In The Trials of Psychedelic Therapy, Matthew Oram traces the early promise and eventual demise of LSD psychotherapy in the United States. While the common perception is that LSD's prohibition terminated legitimate research, Oram draws on files from the Food and Drug Administration and the personal papers of LSD researchers to reveal that the most significant issue was not the drug's illegality, but the persistent question of its efficacy. The landmark Kefauver-Harris Drug Amendments of 1962 installed strict standards for efficacy evaluation, which LSD researchers struggled to meet due to the unorthodox nature of their treatment. Exploring the complex interactions between clinical science, regulation, and therapeutics in American medicine, The Trials of Psychedelic Therapy explains how an age of empirical research and limited government oversight gave way to sophisticated controlled clinical trials and complex federal regulations. Analyzing the debates around how to understand and evaluate treatment efficacy, this book will appeal to anyone with an interest in LSD and psychedelics, as well as mental health professionals, regulators, and scholars of the history of psychiatry, psychotherapy, drug regulation, and pharmaceutical research and development.

A collection of essays examining the current status of the therapeutic potential of hallucinogenic substances, exploring how the drugs can be used to effectively treat a wide range of conditions.